Novartis AG ADR (NVS)vsSerina Therapeutics Inc (SER)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
SER
Serina Therapeutics Inc
$1.83
-1.08%
HEALTHCARE · Cap: $27.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 43521438% more annual revenue ($56.58B vs $130,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SER
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
-24.8%
Fair Value
$1.49
Current Price
$1.83
$0.34 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 154.9% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
ROE of -8159.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.82 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while SER is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 21/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is an innovative biotechnology firm dedicated to addressing unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This advanced technology enhances the efficacy of therapies, significantly improving patient outcomes while positioning the company for sustainable growth in the competitive biopharmaceutical landscape. With a robust pipeline of product candidates and strategic collaborations, Serina is poised to transform healthcare solutions, underscoring its commitment to delivering value for investors and advancing therapeutic possibilities.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?